Fig. 1.

Changes in tumor burden after atezolizumab plus bevacizumab combination therapy. Representative images at baseline (before atezolizumab plus bevacizumab treatment), at different times after systemic therapy initiation and after right hepatectomy operation (OP). The red arrowhead indicates the target lesion, which shrank significantly after treatment; red arrows indicate several nontarget lesions, which resolved completely thereafter; and white arrowheads indicate the huge tumor, which was treated with transarterial chemoembolization before systemic therapy and was resected upon progression